SCHEMBL17010276

SCHEMBL17010276

CCOC(=O)C(NC(=O)c1ccc(O)cc1)C(=O)OCC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 3/20 0.56
CA12 O43570 2/20 0.56
CA1 P00915 2/20 0.56
CA2 P00918 2/20 0.56
CA7 P43166 2/20 0.56
CA9 Q16790 2/20 0.56
CA14 Q9ULX7 2/20 0.56
ESR2 Q92731 1/20 0.56
MPO P05164 1/20 0.47
CYP3A4 P08684 1/20 0.47
KDM5A P29375 1/20 0.47
BLM P54132 1/20 0.47
GFER P55789 1/20 0.47
PMP22 Q01453 1/20 0.47
HIF1A Q16665 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
ALDH1A1 P00352 3/20 0.46
LMNA P02545 2/20 0.46
TSHR P16473 2/20 0.45
CHRM1 P11229 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5782189 0.88 KMT2A (0.54) SMN1; SMN2ALDH1A1LMNATDP1TAS1R3
SCHEMBL4652134 0.85 HTT (0.61) SMN1; SMN2ALDH1A1LMNAMAPTHTT
SCHEMBL14786715 0.85 TAS1R3 (0.43) SMN1; SMN2LMNATAS1R3TAS1R1MAPT
SCHEMBL655688 0.85 ALDH1A1 (0.56) SMN1; SMN2ALDH1A1LMNAMAPTMEN1
SCHEMBL5784044 0.85 SMN1; SMN2 (0.55) CA12CA1CA2CA9SMN1; SMN2
SCHEMBL5424180 0.84 TAS1R3 (0.61) CA12CA1CA2CA9SMN1; SMN2
SCHEMBL14724516 0.83 RAB9A (0.58) CYP3A4SMN1; SMN2ALDH1A1CYP1A2
SCHEMBL6224189 0.80 MAPT (0.49) SMN1; SMN2ALDH1A1LMNATDP1TAS1R3
SCHEMBL17010274 0.79 L3MBTL1 (0.61) SMN1; SMN2ALDH1A1LMNAMAPTMEN1
SCHEMBL9459929 0.79 SMN1; SMN2 (0.52) CA12CA1CA2CA9SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10093631-B2 Bifunctional compounds and use for reducing uric acid levels ACQUIST LLC (US) 2018-10-09 US disclosed
US-20170197923-A1 Bifunctional Compounds and Use for Reducing Uric Acid Levels ACQUIST LLC 2017-07-13 US disclosed
EP-3104861-A1 BIFUNCTIONAL COMPOUNDS AND USE FOR REDUCING URIC ACID LEVELS Warrell, Raymond P., Jr. (US) 2016-12-21 EP disclosed
WO-2015123003-A1 BIFUNCTIONAL COMPOUNDS AND USE FOR REDUCING URIC ACID LEVELS WARRELL RAYMOND P (US) 2015-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170197923-A1 Bifunctional Compounds and Use for Reducing Uric Acid Levels XDH, OAT, ATIC ESR1 3906/4885CA12 1631/4885CA1 2135/4885
US-10093631-B2 Bifunctional compounds and use for reducing uric acid levels XDH, OAT, ATIC ESR1 3906/4885CA12 1631/4885CA1 2135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.